bluebird bio (BLUE) said Tuesday that it is launching a restructuring plan to reduce its workforce by 25%.
The company said the layoffs and other measures will bring it to quarterly cash flow break-even in H2 of next year and reduce cash operating expenses by 20% in Q3 of next year.
Chief Executive Andrew Obenshain said the restructuring will help the gene therapy company attract more investment.
Price: 0.5062, Change: +0.02, Percent Change: +3.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。